MCM
CYCN

MAI Capital Management’s Cyclerion Therapeutics CYCN Stock Holding History

MAI Capital Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100
Closed -$155 – 2686
2026
Q1 		$155 Hold
100
– – ﹤0.01% 4670
2025
Q4 		$127 Hold
100
– – ﹤0.01% 4127
2025
Q3 		$230 Hold
100
– – ﹤0.01% 3697
2025
Q2 		$291 Hold
100
– – ﹤0.01% 3831
2025
Q1 		$250 Hold
100
– – ﹤0.01% 3298
2024
Q4 		$322 Buy
+100
New +$278 ﹤0.01% 3335

Other funds holding CYCN

KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

MAI Capital Management's CYCN Position: Q2 2026 in Review

MAI Capital Management sold out of Cyclerion Therapeutics (CYCN) in Q2 2026, closing a stake of 100 shares — an estimated $155 sold.

MAI Capital Management first reported a position in CYCN in Q4 2024 and held it in 6 quarters. The position peaked at $322 in Q4 2024. 21 funds tracked by Wall St. Rank hold CYCN as of Q2 2026.

  • MAI Capital Management reported no remaining Cyclerion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 100 Cyclerion Therapeutics shares in Q2 2026, an estimated $155.
  • MAI Capital Management first reported a position in Cyclerion Therapeutics in Q4 2024 and held it in 6 quarters.
  • MAI Capital Management's Cyclerion Therapeutics position peaked at $322 in Q4 2024.
  • 21 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.